AUSTRALIAN PRODUCT INFORMATION – SOLU-MEDROL® and SOLU-MEDROL ACT-O-VIAL® (METHYLPREDNISOLONE SODIUM SUCCINATE)

1. NAME OF THE MEDICINE

Methylprednisolone sodium succinate

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SOLU-MEDROL is available in several strengths for intravenous (IV) or intramuscular (IM) administration.

40 mg ACT-O-VIAL System - Each mL (when mixed) contains methylprednisolone sodium succinate equivalent to 40 mg methylprednisolone;

125 mg ACT-O-VIAL System - Each 2 mL (when mixed) contains methylprednisolone sodium succinate equivalent to 125 mg methylprednisolone;

500 mg Vial with Diluent - Each 8 mL (when mixed as directed) contains methylprednisolone sodium succinate equivalent to 500 mg methylprednisolone;

1 g Vial with Diluent - Each 15.6 mL (when mixed as directed) contains methylprednisolone sodium succinate equivalent to 1 g methylprednisolone;

2 g Vial with Diluent - Each 31.2 mL (when mixed as directed) contains methylprednisolone sodium succinate equivalent to 2 g methylprednisolone;

500 mg Plain Vial - Each vial contains methylprednisolone sodium succinate equivalent to 500 mg methylprednisolone;

1 g Plain Vial - Each vial contains methylprednisolone sodium succinate equivalent to 1 g methylprednisolone;

For the full list of excipients, see Section 6.1 List of excipients.

3. PHARMACEUTICAL FORM

SOLU-MEDROL 40 mg and 125 mg ACT-O-VIAL System

- Powder for injection: White freeze dried cake
- Diluent: Clear colourless liquid

SOLU-MEDROL 500 mg, 1 g and 2 g Vials with Diluent

- Powder for injection: White freeze dried cake
- Diluent: Clear colourless liquid

SOLU-MEDROL 500 mg and 1 g Plain Vials

- Powder for injection: White freeze dried cake

When necessary, the pH of each formula was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8 and the tonicities are, for the 40 mg per mL solution, 0.50 osmolar; for the 125 mg per 2 mL, 500 mg per 8 mL and 1 g per 16 mL solutions, 0.40 osmolar; for the 2 g per 31.2 mL solutions, 0.42 osmolar (Isotonic saline = 0.28 osmolar).

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

When oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, SOLU-MEDROL Powder for Injection is indicated only for intravenous or intramuscular use in the following conditions:

**Endocrine Disorders**

- Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).

- Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used).

- Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.

- Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.

- Congenital adrenal hyperplasia

- Nonsuppurative thyroiditis

- Hypercalcaemia associated with cancer.

**Rheumatic Disorders**

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

- Ankylosing spondylitis

- Psoriatic arthritis
- Acute and subacute bursitis
- Epicondylitis
- Synovitis of osteoarthritis
- Acute gouty arthritis
- Acute nonspecific tenosynovitis
- Post-traumatic osteoarthritis
- Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy).

**Collagen Disease**

During an exacerbation or as maintenance therapy in selected cases of:

- Systemic lupus erythematosus
- Systemic dermatomyositis (polymyositis)
- Acute rheumatic carditis.

**Dermatological Diseases**

- Bullous dermatitis herpetiformis
- Pemphigus
- Severe psoriasis
- Severe seborrhoeic dermatitis
- Exfoliative dermatitis
- Mycosis fungoides
- Severe erythema multiforme (Stevens-Johnson Syndrome).

**Allergic States**

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:

- Bronchial asthma
- Drug hypersensitivity reactions
- Contact dermatitis
• Urticarial transfusion reactions
• Atopic dermatitis
• Serum sickness
• Acute noninfectious laryngeal oedema (adrenaline is the drug of first choice).

**Ophthalmic Diseases**

Severe acute and chronic allergic and inflammatory processes involving the eye, such as:

• Allergic corneal marginal ulcers
• Allergic conjunctivitis
• Chorioretinitis
• Anterior segment inflammation
• Herpes zoster ophthalmicus
• Iritis, iridocyclitis
• Diffuse posterior uveitis and choroiditis
• Keratitis
• Optic neuritis
• Sympathetic ophthalmia.

**Gastrointestinal Diseases**

To tide the patient over a critical period of the disease in:

• Ulcerative colitis (systemic therapy)
• Regional enteritis (systemic therapy).

**Respiratory Diseases**

• Symptomatic sarcoidosis
• Berylliosis
• Aspiration pneumonitis
• Loeffler’s syndrome not manageable by other means
• Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy.
Haematologic Disorders

- Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)
- Secondary thrombocytopenia in adults
- Acquired (autoimmune) haemolytic anaemia
- Erythroblastopenia (RBC anaemia)
- Congenital (erythroid) hypoplastic anaemia.

Neoplastic Diseases

For palliative management of:

- Leukaemias and lymphomas in adults
- Acute leukaemia of childhood.

Oedematous States

- To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus.

Nervous System

- Acute exacerbations of multiple sclerosis.

Miscellaneous

- Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
- Trichinosis with neurologic or myocardial involvement.
- SOLU-MEDROL is beneficial as adjunctive therapy in the treatment of acquired immunodeficiency syndrome (AIDS) patients with moderate to severe *Pneumocystis jiroveci* pneumonia (PCP) when given within the first 72 hours of initial anti-pneumocystis treatment.

4.2 Dose and method of administration

Dosage

SOLU-MEDROL may be administered by intravenous or intramuscular injection or by intravenous infusion. The preferred method for initial emergency use is intravenous injection. To administer by intravenous (or intramuscular) injection, prepare solution as directed. The desired dose, if 250 mg or less, may be administered intravenously over at least 5 minutes. Intramuscular injections (250 mg or less) should be injected slowly into a large muscle. If
desired, the medication may be administered in diluted solutions by adding Water for Injections or other suitable diluent (see Method of Administration) to the ACT-O-VIAL and withdrawing the indicated dose.

Methylprednisolone sodium succinate is so extremely soluble in water that it may be administered in a small volume of diluent and is especially well suited for intravenous use in situations in which high blood levels of methylprednisolone are required rapidly.

Dosage requirements are variable and must be individualised on the basis of the disease under treatment, its severity and the response of the patient over the entire duration of treatment. A risk/benefit decision must be made in each individual case on an ongoing basis.

The lowest possible dose of corticosteroid should be used to control the condition under treatment for the minimum period. The proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage, which will maintain an adequate clinical response, is reached.

If after long-term therapy the drug is to be stopped, it needs to be withdrawn gradually rather than abruptly (see Section 4.4 Special warnings and precautions for use).

Following the initial emergency period, consideration should be given to employing a longer acting injectable preparation or an oral preparation.

As adjunctive therapy in life-threatening conditions, administer 30 mg/kg IV over a period of at least 30 minutes (see Sections 4.4 Special warnings and precautions for use and 4.9 Overdose). The dose may be repeated every 4 to 6 hours for up to 48 hours.

In general, high dose corticosteroid therapy should be continued only until the patient’s condition has stabilised; usually not beyond 48 to 72 hours.

Although the adverse effects associated with high dose short-term corticoid therapy are uncommon, peptic ulceration may occur. Prophylactic antacid therapy may be indicated.

Methylprednisolone IV pulses, consisting of administration of 250 mg/day or above for a few days (usually ≤ 5 days) may be suitable during exacerbation episodes or conditions unresponsive to standard therapy, such as: rheumatic disorders, systemic lupus erythematosus, oedematous states, such as glomerulonephritis or lupus nephritis. In acute exacerbations of multiple sclerosis, administer IV pulses of 500 mg/day or 1g/day for 3 or 5 days over at least 30 minutes (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone).

As adjunctive therapy in other indications, initial dosage will vary from 10 to 500 mg intravenously, depending on the clinical condition. Larger doses may be required for short-term management of severe, acute conditions. Initial doses up to 250 mg, should be administered intravenously over a period of at least 5 minutes, while larger doses should be administered over at least 30 minutes. Subsequent doses may be administered intravenously or intramuscularly at intervals dictated by the patient’s response and clinical condition. Corticoid therapy is an adjunct to, and not replacement for conventional therapy.
**Use in Paediatrics**

Dosage may be reduced for infants and children but should be selected based on the severity of the condition and response of the patient rather than on the age or weight of the patient. The paediatric dosage should not be less than 0.5 mg per kg every 24 hours.

**Warning** - Benzyl alcohol (as contained in the accompanying diluent for the 500 mg, 1 g and 2 g vials) has been reported to be associated with a fatal “Gasping Syndrome” in premature infants (see Section 4.4 Special warnings and precautions for use, Paediatric Use).

Dosage must be decreased or discontinued gradually when the drug has been administered for more than a few days. If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. Routine laboratory studies, such as urinalysis, two-hour postprandial blood glucose, determination of blood pressure and body weight, and a chest X-ray should be made at regular intervals during prolonged therapy. The state of the upper GI tract should be monitored in patients with a history of ulceration or significant dyspepsia.

**Summary of Dosage and Administration Recommendations**

1. For Intravenous Use

<table>
<thead>
<tr>
<th>DOSE</th>
<th>ADMINISTRATION TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2 g</td>
<td>at least 30 minutes</td>
</tr>
<tr>
<td>1 g</td>
<td>at least 30 minutes</td>
</tr>
<tr>
<td>500 mg</td>
<td>at least 30 minutes</td>
</tr>
<tr>
<td>250 mg</td>
<td>at least 5 minutes</td>
</tr>
<tr>
<td>125 mg</td>
<td>at least 5 minutes</td>
</tr>
<tr>
<td>≤ 40 mg</td>
<td>at least 5 minutes</td>
</tr>
</tbody>
</table>

2. For Intramuscular Use

Intramuscular injections (250 mg or less) should be injected slowly into a large muscle.

**Method of Administration**

**Directions for Using the ACT-O-VIAL System**

1. Tap to ensure that the powder is at base of vial and away from the central stopper.
2. Place the Act-O-Vial on a flat, stable surface and hold with one hand.
3. Press down firmly on the plastic activator with the palm of the other hand to force diluent into the lower compartment.
4. Gently mix the solution by turning the vial upside down a number of times. **DO NOT SHAKE THE VIAL.**
5. Remove plastic tab covering centre of stopper.


**Note: Steps 1-6 must be completed before proceeding.**

7. Whilst on a flat surface, insert needle **squarely through centre** of stopper until tip is just visible.

8. Invert vial to allow the solution to flow into the top compartment and withdraw the dose.

**Reconstitution of SOLU-MEDROL**

**SOLU-MEDROL should be reconstituted with the diluent where this is provided.** Where no diluent is provided, the sterile powder should be reconstituted using Bacteriostatic Water for Injections with benzyl alcohol or Sterile Water for Injections. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit.

**It is recommended that the reconstituted solution of SOLU-MEDROL be used immediately upon preparation.**

The volume of diluent recommended and the resulting concentration is as follows:

<table>
<thead>
<tr>
<th>Product Strength</th>
<th>Diluent Volume Recommended</th>
<th>Resulting Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 mg</td>
<td>4 or 8 mL</td>
<td>125 or 62.5 mg/mL</td>
</tr>
<tr>
<td>1 g</td>
<td>8 or 16 mL</td>
<td>125 or 62.5 mg/mL</td>
</tr>
</tbody>
</table>

**IMPORTANT** - Use only the accompanying diluent to reconstitute SOLU-MEDROL Vial with Diluent (which is Bacteriostatic Water for Injections with benzyl alcohol) and SOLU-MEDROL ACT-O-VIALS (which is sterile Water for Injections). Bacteriostatic Water for Injections with benzyl alcohol or sterile Water for Injections may be used when reconstituting SOLU-MEDROL Plain Vials.

Because of possible physical incompatibilities, SOLU-MEDROL should not be diluted or mixed with other solutions (see section 6.2 Incompatibilities).

**Preparation of Solutions for Intravenous Infusion**

To prepare solutions for intravenous infusion, first prepare the solution for injection as directed above. This solution may then be added to Glucose Intravenous Infusion 5%, Sodium Chloride Intravenous Infusion 0.9% or Sodium Chloride 0.9% and Glucose 5% Intravenous Infusion; the resulting admixtures should be used immediately. This solution is for SINGLE USE ONLY.
4.3 Contraindications

Methylprednisolone sodium succinate is contraindicated:

- in patients who have systemic fungal infections
- in patients with known hypersensitivity to methylprednisolone or any component of the formulation. The 40 mg ACT-O-VIAL presentation includes lactose produced from cow’s milk. This presentation may contain trace amounts of milk ingredients and is therefore contraindicated in patients with a known or suspected hypersensitivity to cow’s milk or its components, or to other dairy products.

SOLU-MEDROL (METHYLPREDNISOLONE SODIUM SUCCINATE) IS CONTRAINDICATED FOR INTRATHecal, EPIDURAL OR LOCAL INJECTION, OR ANY OTHER UNSPECIFIED ROUTE OF ADMINISTRATION.

Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids (see Section 4.4 Special warnings and precautions for use, Immunosuppressant Effects/Increased Susceptibility to Infections).

4.4 Special warnings and precautions for use

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual. Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Immunosuppressant Effects/Increased Susceptibility to Infections

Corticosteroids increase susceptibility to infection, may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localise infection when corticosteroids are used. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic organisms, in any location in the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids.

Similarly, corticosteroids should be used with great care in patients with known or suspected parasitic infections such as Strongyloides (threadworm) infestation, which may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicaemia.

Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the
response to such vaccines may be diminished. Indicated immunisation procedures may be undertaken in patients receiving non-immunosuppressive doses of corticosteroids.

The use of SOLU-MEDROL Powder for Injection in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with appropriate anti-tuberculosis regimen.

If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

The use of SOLU-MEDROL in patients with AIDS (as in the adjunctive treatment of *Pneumocystis jiroveci* pneumonia) may be associated with an increased rate of reactivation of tuberculosis. Consideration should therefore be given to the administration of antmycobacterial therapy if corticosteroids are used in this high risk group. Such patients should also be observed for the activation of other latent infections, and judicious examinations of sputum/bronchoalveolar fluid should be made for the presence of other infectious agents.

Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

A study has failed to establish the efficacy of SOLU-MEDROL in the treatment of sepsis syndrome and septic shock. Thus, routine use in septic shock is not recommended. The study also suggests that treatment of these conditions with SOLU-MEDROL may increase the risk of mortality in certain patients (i.e. patients with elevated serum creatinine levels or patients who develop secondary infections after SOLU-MEDROL).

**Immune System Effects**

Allergic reactions may occur. Because rare instances of skin reactions and anaphylactic/anaphylactoid reactions (e.g. bronchospasm) have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug.

In patients receiving the 40 mg presentation of methylprednisolone sodium succinate during the treatment for acute allergic conditions and where these symptoms worsen or any new allergic symptoms occur, consideration should be given to the potential for hypersensitivity reactions to cow’s milk ingredients (see Section 4.3 Contraindications). If appropriate, administration of methylprednisolone sodium succinate should be stopped, and the patient’s condition should be treated accordingly. Alternative treatments, including the use of corticosteroid formulations that do not contain ingredients produced from cow’s milk, should be considered for acute allergy management, where appropriate.

**Cardiac Effects**

There are reports of cardiac arrhythmias and/or circulatory collapse and/or cardiac arrest following the rapid administration of large IV doses of SOLU-MEDROL (greater than 0.5 g administered over a period of less than 10 minutes). Bradycardia has been reported during or after the administration of large doses of methylprednisolone sodium succinate, and may be unrelated to the speed or duration of infusion (see Sections 4.2 Dose and method of administration, 4.8 Adverse effects (undesirable effects) and 4.9 Overdose).
Adverse effects of glucocorticoids on the cardiovascular system, such as dyslipidaemia and hypertension, may predispose treated patients with existing cardiovascular risk factors to additional cardiovascular effects if high doses and prolonged courses are used. Accordingly, corticosteroids should be employed judiciously in such patients and risk modification and additional cardiac monitoring may need to be considered. Low dose and alternate-day therapy may reduce the incidence of complications in corticosteroid therapy.

Use of systemic corticosteroid is not recommended in patients with congestive heart failure.

**Vascular Effects**

Thrombosis including venous thromboembolism has been reported to occur with corticosteroids. As a result corticosteroids should be used with caution in patients who have or may be predisposed to thromboembolic disorders.

Corticosteroids should be used with caution in patients with hypertension.

**Endocrine Effects**

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated.

Pharmacologic doses of corticosteroids administered for prolonged periods may result in hypothalamic-pituitary-adrenal (HPA) suppression (secondary adrenocortical insufficiency). The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration, and duration of glucocorticoid therapy. This effect may be minimised by use of alternate-day therapy.

In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly.

Drug-induced secondary adrenocortical insufficiency may be minimised by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.

A steroid “withdrawal syndrome”, seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.

Because glucocorticoids can produce or aggravate Cushing’s syndrome, glucocorticoids should be avoided in patients with Cushing’s disease.

There is an enhanced effect of corticosteroids in patients with hypothyroidism.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.
Ocular Effects

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts and nuclear cataracts (particularly in children), exophthalmos or increased intraocular pressure which may result in glaucoma with possible damage to the optic nerves and may enhance the establishment of secondary ocular infections due to fungi or viruses.

Corticosteroid therapy has been associated with central serous chorioretinopathy, which may lead to retinal detachment.

If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes.

Psychiatric Effects

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Potentially severe psychiatric adverse reactions may occur with systemic steroids (see Section 4.8 Adverse effects (undesirable effects)). Symptoms typically emerge within a few days or weeks of starting treatment. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary.

Psychological effects have been reported upon withdrawal of corticosteroids; the frequency is unknown. Patients/caregivers should be encouraged to seek medical attention if psychological symptoms develop in the patient, especially if depressed mood or suicidal ideation is suspected. Patients/caregivers should be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids.

Gastrointestinal Effects

High doses of corticosteroids may produce acute pancreatitis.

Corticosteroid therapy may mask the symptoms of peptic ulcer so that perforation or haemorrhage may occur without significant pain. Glucocorticoid therapy may mask peritonitis or other signs or symptoms associated with gastrointestinal disorders such as perforation, obstruction or pancreatitis. In combination with non-steroidal anti-inflammatory drugs (NSAIDs), the risk of developing gastrointestinal ulcers is increased.

Corticosteroids should be used with caution in non-specific ulcerative colitis if there is a probability of impending perforation, abscess, or other pyogenic infection, diverticulitis, fresh intestinal anastomoses, or active or latent peptic ulcer.

Nervous System Effects

Use of corticosteroids is not recommended in patients with seizure disorders.
Corticosteroids should be used with caution in patients with myasthenia gravis (see Section 4.4 Special warnings and precautions for use, Musculoskeletal Effects).

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see Section 4.2 Dose and method of administration).

Severe medical events have been reported in association with the intrathecal/epidural routes of administration (see Section 4.8 Adverse effects (undesirable effects)).

There have been reports of epidural lipomatosis in patients taking corticosteroids, typically with long-term use at high doses.

**Musculoskeletal Effects**

An acute myopathy has been described with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g. myasthenia gravis) or in patients receiving concomitant therapy with anticholinergics, such as neuromuscular blocking drugs (e.g. pancuronium). This acute myopathy is generalised, may involve ocular and respiratory muscles, and may result in quadriplegia. Elevations of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Corticosteroids should be used with caution in osteoporosis. Osteoporosis is a common but infrequently recognised adverse effect associated with a long-term use of large doses of glucocorticoid.

**Metabolism and Nutrition**

Corticosteroids, including methylprednisolone, can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term corticosteroid therapy to diabetes mellitus.

**Injury, Poisoning and Procedural Complications**

Systemic corticosteroids are not indicated for, and should therefore not be used to treat traumatic brain injury. A large multicentre randomised study in patients administered corticosteroid therapy after significant head injury revealed an increased risk of mortality in the corticosteroid group compared to the placebo group.

**Other**

Aspirin and non-steroidal anti-inflammatory agents should be used cautiously in conjunction with corticosteroids (see Section 4.5 Interactions with other medicines and other forms of interactions, Table 2, NSAIDs).

Benzyl alcohol is contained in the accompanying diluent for the 500 mg, 1 g and 2 g vials. Benzyl alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants (see Section 4.4 Special warnings and precautions for use, Paediatric Use). The 40 mg ACT-O-VIALS and the 125 mg ACT-O-VIALS do not contain benzyl alcohol.
In post-marketing experience tumour lysis syndrome (TLS) has been reported in patients with malignancies, including haematological malignancies and solid tumours, following the use of systemic corticosteroids alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with tumours that have a high proliferative rate, high tumour burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken.

**Use in Hepatic Impairment**

Drug-induced liver injury such as acute hepatitis can result from cyclical pulsed IV methylprednisolone (usually at doses of 1 g/day). The time to onset of acute hepatitis can be several weeks or longer. Resolution of the adverse event has been observed after treatment was discontinued. Serious hepatotoxicity has been reported.

There is an enhanced effect of corticosteroids in patients with cirrhosis.

**Use in Renal Impairment**

Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.

Corticosteroids should be used with caution in patients with renal insufficiency.

**Use in the Elderly**

Caution is recommended with prolonged corticosteroid treatment in the elderly due to a potential increased risk for osteoporosis, as well as increased risk for fluid retention with possible resultant hypertension.

**Paediatric Use**

Benzyl alcohol is contained in the accompanying diluent for the 500 mg, 1 g and 2 g vials. The 40 mg ACT-O-VIALS and the 125 mg ACT-O-VIALS do not contain benzyl alcohol. Benzyl alcohol is associated with severe adverse effects, including fatal “gasping syndrome”, in paediatric patients. The minimum amount of benzyl alcohol at which toxicity may occur is unknown. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys’ capacity to detoxify the chemical. Premature and low birth weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Growth may be suppressed in children receiving long-term, daily, divided-dose glucocorticoid therapy and use of such a regimen should be restricted to the most urgent indications. Alternate-day glucocorticoid therapy usually avoids or minimises this side effect.

Infants and children on prolonged corticosteroid therapy are at special risk from raised intracranial pressure.

High doses of corticosteroids may produce pancreatitis in children.
Hypertrophic cardiomyopathy may develop after administration of methylprednisolone to prematurely born infants, therefore appropriate diagnostic evaluation and monitoring of cardiac function and structure should be performed.

**Effects on Laboratory Tests**

Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

**4.5 Interactions with other medicines and other forms of interactions**

Methylprednisolone has a wide spectrum of clinical use and is therefore used with numerous concurrent drugs. The interactions summarised in the following table are of known or likely clinical significance. The need for dosage adjustment of either medication will depend on the clinical situation, the dose regimen prescribed and the observed clinical response. The interactions listed have either pharmacokinetic or pharmacodynamic basis.

Methylprednisolone is a cytochrome P450 enzyme (CYP) substrate and is mainly metabolised by the CYP3A4 enzyme. CYP3A4 catalyses 6β-hydroxylation of steroids, the essential Phase I metabolic step for both endogenous and synthetic corticosteroids. Many other compounds are also substrates of CYP3A4, some of which (as well as other drugs) have been shown to alter glucocorticoid metabolism by induction (upregulation) or inhibition of the CYP3A4 enzyme.

**CYP3A4 Inhibitors**

Drugs that inhibit CYP3A4 activity generally decrease hepatic clearance, resulting in increased plasma concentrations of corticosteroids. Co-administration of these substances may require titration of corticosteroid dosage to reduce the risk of adverse effects and avoid steroid toxicity.

**CYP3A4 Inducers**

Drugs that induce CYP3A4 activity generally increase hepatic clearance, resulting in decreased plasma concentrations of corticosteroids. Co-administration of these substances may require an increase in corticosteroid dosage to achieve the desired result.

**CYP3A4 Substrates**

In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with co-administration.

The most common and/or clinically important drug interactions or effects resulting from co-administration of SOLU-MEDROL and examples of CYP3A4 inhibitors, inducers and substrates are provided in Table 1 and 2. Table 1 and 2 should be used in conjunction with the detailed information provided above.
Table 1 Examples of CYP3A4 inhibitors, inducers and substrates that interact with SOLU-MEDROL.

<table>
<thead>
<tr>
<th></th>
<th>CYP3A4 Inhibitor</th>
<th>CYP3A4 Inducers</th>
<th>CYP3A4 Substrates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotics/Antifungal Agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Troleandomycin</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>• Erythromycin</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>• Ketoconazole</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>• Itraconazole</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Antibiotics/Antitubercular Agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Rifampicin</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>• Rifabutin</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>• Isoniazid (also see Table 2)</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Anticonvulsants</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Carbamazepine</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>• Phenobarbital(phenobarbitone)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Phenytoin</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Antiemetics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Aprepitant</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>• Fosaprepitant</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antivirals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• HIV Protease Inhibitors e.g. indinavir and ritonavir</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Calcium Channel Blocker</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Diltiazem</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contraceptives (Oral)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Ethinylestradiol</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
• Norethindrone

Grapefruit Juice

Immunosuppressants
• Ciclosporin (also see Table 2)
• Cyclophosphamide
• Tacrolimus

Macrolide Antibacterial Agents
• Clarithromycin

<table>
<thead>
<tr>
<th>Class of Drug/Drug(s) Involved</th>
<th>Drug(s) Affected/Mechanism/Clinical Implication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotic/Antifungal Therapy</td>
<td>CYP3A4 inhibitor. Co-administration may result in reduced corticosteroid clearance, enhanced clinical effects and an increased risk of adverse effects of methylprednisolone.</td>
</tr>
<tr>
<td>- Troleandomycin</td>
<td></td>
</tr>
<tr>
<td>- Erythromycin</td>
<td></td>
</tr>
<tr>
<td>- Ketoconazole</td>
<td></td>
</tr>
<tr>
<td>Antibiotics/Antitubercular Therapy</td>
<td>CYP3A4 inducer. Increased hepatic clearance which may reduce efficacy of corticosteroid. Dosage adjustment may be required.</td>
</tr>
<tr>
<td>- Rifampicin</td>
<td></td>
</tr>
<tr>
<td>Anticholinesterase</td>
<td>Corticosteroids may reduce the effects of anticholinesterases in myasthenia gravis which may result in precipitation of myasthenic crisis.</td>
</tr>
<tr>
<td>- Neostigmine</td>
<td></td>
</tr>
<tr>
<td>- Pyridostigmine</td>
<td></td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>Effect on anticoagulant is variable. Enhanced as well as diminished effects of anticoagulants with co-administration with corticosteroids have been reported. Coagulation indices should be monitored. Adjust dose accordingly to maintain desired anticoagulant effects.</td>
</tr>
<tr>
<td>- Oral anticoagulants or heparin</td>
<td></td>
</tr>
<tr>
<td>Class of Drug/Drug(s) Involved</td>
<td>Drug(s) Affected/Mechanism/Clinical Implication</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Anticonvulsants</strong></td>
<td></td>
</tr>
<tr>
<td>- Phenobarbital (phenobarbitone)</td>
<td>CYP3A4 inducers</td>
</tr>
<tr>
<td>- Phenytoin</td>
<td>Co-administration may increase clearance of methylprednisolone leading to reduced methylprednisolone efficacy. Monitor clinical response. Adjust dose if necessary.</td>
</tr>
<tr>
<td><strong>Antidiabetic Drugs</strong></td>
<td></td>
</tr>
<tr>
<td>- Insulin</td>
<td>Diabetogenic effects of corticosteroid may impair glucose control of the antidiabetic agents. Monitor glucose levels and adjust dose of antidiabetic therapy if used concurrently with corticosteroids.</td>
</tr>
<tr>
<td>- Glibenclamide</td>
<td></td>
</tr>
<tr>
<td>- Metformin</td>
<td></td>
</tr>
<tr>
<td><strong>All Antihypertensive Agents</strong></td>
<td>Antihypertensive agents are affected with co-administration due to mineralocorticoid effect of corticoid leading to raised blood pressure. May result in partial loss of hypertensive control.</td>
</tr>
<tr>
<td><strong>Antitubercular Agents</strong></td>
<td></td>
</tr>
<tr>
<td>- Isoniazid</td>
<td>CYP3A4 inhibitor.</td>
</tr>
<tr>
<td></td>
<td>In addition there is a potential effect of methylprednisolone to increase the acetylation rate and clearance of isoniazid.</td>
</tr>
<tr>
<td><strong>Aromatase Inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>- Aminoglutethimide</td>
<td>Aminoglutethimide induced adrenal suppression may exacerbate endocrine changes caused by prolonged glucocorticoid treatment.</td>
</tr>
<tr>
<td><strong>Cardioactive Drugs</strong></td>
<td></td>
</tr>
<tr>
<td>- Digoxin and related glycosides</td>
<td>Corticosteroid induced potassium loss (mineralocorticoid effect). Potentiation of digoxin toxicity.</td>
</tr>
<tr>
<td><strong>Diuretic</strong></td>
<td></td>
</tr>
<tr>
<td>- All potassium losing diuretics e.g. frusemide, thiazide</td>
<td>Excessive potassium loss may be experienced with concurrent use of corticosteroids and potassium depleting diuretics or carbonic anhydrase inhibitors. There is enhanced toxicity with co-administration and an increased risk of hypokalaemia. Monitor K+ levels and supplement if necessary.</td>
</tr>
<tr>
<td>- Carbonic anhydrase inhibitors e.g. acetazolamide</td>
<td></td>
</tr>
<tr>
<td><strong>HIV Protease Inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>- e.g. indinavir, ritonavir</td>
<td>Co-administration may increase plasma concentrations of corticosteroids. Corticosteroids may reduce plasma concentrations of HIV-protease inhibitors, by inducing their metabolism.</td>
</tr>
<tr>
<td>Class of Drug/Drug(s) Involved</td>
<td>Drug(s) Affected/Mechanism/Clinical Implication</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Immunising Agents</strong></td>
<td></td>
</tr>
<tr>
<td>- Live vaccine e.g. poliomyelitis, BCG, mumps, measles, rubella, smallpox.</td>
<td>Co-administration may result in corticosteroid induced immunosuppression. There may be an increased toxicity from vaccine. Disseminated viral disease may occur (see Sections 4.3 Contraindications and 4.4 Special warnings and precautions for use).</td>
</tr>
<tr>
<td>- Killed Virulent Vaccines</td>
<td>Co-administration may result in impaired immune response and/or reduced response to vaccine (see Sections 4.3 Contraindications and 4.4 Special warnings and precautions for use).</td>
</tr>
<tr>
<td><strong>Immunosuppressants</strong></td>
<td></td>
</tr>
<tr>
<td>- Methotrexate</td>
<td>Synergistic effect on disease state. Since concurrent administration of these agents results in a mutual inhibition of metabolism, it is possible that convulsions and other adverse events associated with the individual use of either drug may be more likely to occur. May allow reduced dose of corticosteroid. Increased activity of both ciclosporin and corticosteroids with co-administration. Convulsions have been reported with concurrent use of methylprednisolone and ciclosporin. Monitor ciclosporin A levels. Adjust dose as necessary.</td>
</tr>
<tr>
<td>- Ciclosporin</td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergics</strong></td>
<td></td>
</tr>
<tr>
<td>- Neuromuscular Blocking Agent e.g. pancuronium, vecuronium</td>
<td>Partial reversal of neuromuscular block. Acute myopathy has been reported with concurrent use of high doses of corticosteroids and anticholinergics, such as neuromuscular blocking agents (see Section 4.4 Special warnings and precautions for use). Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking corticosteroids. This reaction may be expected with all competitive neuromuscular blockers.</td>
</tr>
<tr>
<td><strong>Potassium depleting agents</strong></td>
<td></td>
</tr>
<tr>
<td>- Diuretics</td>
<td>When administered with potassium depleting agents, patients should be observed closely for development of hypokalaemia as there is an increased risk with concurrent use.</td>
</tr>
<tr>
<td>- Amphotericin B, xanthines or beta 2 agonists</td>
<td></td>
</tr>
<tr>
<td>Class of Drug/Drug(s) Involved</td>
<td>Drug(s) Affected/Mechanism/Clinical Implication</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Psychotherapeutic</strong></td>
<td></td>
</tr>
<tr>
<td>- CNS active drugs such as</td>
<td>Co-administration may potentiate CNS effects</td>
</tr>
<tr>
<td>Anxiolytics and</td>
<td>of corticosteroid. As the CNS active drug is</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>affected with co-administration, recurrence</td>
</tr>
<tr>
<td></td>
<td>or poor control of CNS symptoms may result.</td>
</tr>
<tr>
<td></td>
<td>May require dose adjustment to obtain desired</td>
</tr>
<tr>
<td></td>
<td>effect.</td>
</tr>
<tr>
<td><strong>NSAIDs</strong></td>
<td></td>
</tr>
<tr>
<td>- Aspirin</td>
<td>There may be increased incidence of</td>
</tr>
<tr>
<td></td>
<td>gastrointestinal bleeding and ulceration when</td>
</tr>
<tr>
<td></td>
<td>corticosteroids are given with NSAIDs.</td>
</tr>
<tr>
<td></td>
<td>Methylprednisolone may increase the clearance</td>
</tr>
<tr>
<td></td>
<td>of high dose aspirin, which can lead to</td>
</tr>
<tr>
<td></td>
<td>decreased salicylate serum levels. Discontinuation</td>
</tr>
<tr>
<td></td>
<td>of methylprednisolone treatment can lead to</td>
</tr>
<tr>
<td></td>
<td>raised salicylate serum levels, which could</td>
</tr>
<tr>
<td></td>
<td>lead to an increased risk of salicylate</td>
</tr>
<tr>
<td></td>
<td>toxicity.</td>
</tr>
<tr>
<td><strong>Sympathomimetic Agents</strong></td>
<td></td>
</tr>
<tr>
<td>- Salbutamol</td>
<td>Co-administration leading to increased response</td>
</tr>
<tr>
<td></td>
<td>to sympathetic agents with resulting increased</td>
</tr>
<tr>
<td></td>
<td>efficacy and potentially increased toxicity.</td>
</tr>
</tbody>
</table>

### 4.6 Fertility, pregnancy and lactation

#### Effects on Fertility

Animal studies on the effects of methylprednisolone did not show an adverse impact on fertility in male and female rats treated with methylprednisolone aceponate at subcutaneous doses up to 0.1 mg/kg/day, although there was an increase in the number of non-viable fetuses. Other corticosteroids have been shown to impair fertility and reduce embryonic viability in studies in mice and rats.

#### Use in Pregnancy – Pregnancy Category A

Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. In animal reproduction studies, glucocorticoids such as methylprednisolone have been shown to increase the incidence of malformations (cleft palate, ventricular septal defect, skeletal malformations), embryo-fetal lethality (e.g. increase in resorptions), intra-uterine growth retardation and abortions.

There is limited data on the use of methylprednisolone sodium succinate in human pregnancies, and animal reproduction studies have not been done. Methylprednisolone sodium succinate should be used in pregnancy only after a careful assessment of the benefit-risk ratio to the mother and fetus.

Some corticosteroids readily cross the placenta. An increased incidence of low birth weights in infants born of mothers receiving corticosteroids has been reported.
Infants exposed *in utero* to substantial doses of corticosteroids must be carefully observed and evaluated for signs of adrenal insufficiency.

Cataracts have been observed in infants born to mothers treated with long-term corticosteroids during pregnancy.

Benzyl alcohol can cross the placenta (see Section 4.4 Special warnings and precautions for use, Paediatric Use).

**Use in Lactation**

Corticosteroids are excreted in breast milk.

Corticosteroids distributed into breast milk may suppress growth and interfere with endogenous glucocorticoid production in nursing infants. This medicinal product should be used during breast feeding only after a careful assessment of the benefit-risk ratio to the mother and infant.

**4.7 Effects on ability to drive and use machines**

The effect of corticosteroids on the ability to drive or use machinery has not been systematically evaluated. Undesirable effects, such as dizziness, vertigo, visual disturbances, and fatigue are possible after treatment with corticosteroids (see Section 4.8 Adverse effects (undesirable effects)). If affected, patients should not drive or operate machinery.

**4.8 Adverse effects (undesirable effects)**

Serious undesirable adverse events are also mentioned under the Section 4.4 Special warnings and precautions for use.

The following adverse reactions have been reported with the following contraindicated routes of administration: Intrathecal/Epidural: Arachnoiditis, functional gastrointestinal disorder/bladder dysfunction, headache, meningitis, paraparesis/paraplegia, seizure, sensory disturbance.

The adverse effects are listed in the table below by system organ class.

**Infections and Infestations**

Opportunistic infection, infection\(^a\), peritonitis\(^b\).

**Blood and Lymphatic System Disorders**

Leucocytosis.

**Immune System Disorders**

Drug hypersensitivity\(^c\), anaphylactic reaction, anaphylactoid reaction.

**Endocrine Disorders**
Cushingoid, hypothalamic-pituitary-adrenal axis suppression, steroid withdrawal syndrome, adrenal insufficiency.

**Metabolism and Nutrition Disorders**

Metabolic acidosis, sodium retention, fluid retention, alkalosis hypokalaemic, dyslipidaemia, glucose tolerance impaired, increased insulin requirement (or oral hypoglycaemic agents in diabetics), lipomatosis, increased appetite (which may result in weight increased).

**Psychiatric Disorders**

Affective disorder (including depressed mood, euphoric mood, affect lability, drug dependence, suicidal ideation), psychotic disorder (including mania, delusion, hallucination and schizophrenia), mental disorder, personality change, confusional state, anxiety, mood swings, abnormal behaviour, insomnia, irritability.

**Nervous System Disorders**

Epidural lipomatosis, intracranial pressure increased (with papilloedema [benign intracranial hypertension]), seizure, amnesia, cognitive disorder, dizziness, headache.

**Eye Disorders**

Chorioretinopathy, cataract, glaucoma, exophthalmos, vision blurred.

**Ear and Labyrinth Disorders**

Vertigo.

**Cardiac Disorders**

Cardiac failure congestive (in susceptible patients), myocardial rupture, arrhythmia.

**Vascular Disorders**

Thrombosis, hypertension, hypotension.

**Respiratory, Thoracic and Mediastinal Disorders**

Pulmonary embolism, hiccups.

**Gastrointestinal Disorders**

Peptic ulcer (with possible peptic ulcer perforation and peptic ulcer haemorrhage), intestinal perforation, gastric haemorrhage, pancreatitis, oesophagitis ulcerative, oesophagitis, vomiting, abdominal distension, abdominal pain, diarrhoea, dyspepsia, nausea.

**Hepatobiliary Disorders**

Hepatitis.
**Skin and Subcutaneous Tissue Disorders**

Angioedema, hirsutism, petechiae, ecchymosis, subcutaneous atrophy, skin atrophy, erythema, hyperhidrosis, skin striae, rash, pruritus, urticaria, acne, skin hyperpigmentation, skin hypopigmentation.

**Musculoskeletal and Connective Tissue Disorders**

Muscular weakness, myalgia, myopathy, muscle atrophy, osteoporosis, osteonecrosis, pathological fracture, neuropathic arthropathy, arthralgia, growth retardation.

**Reproductive System and Breast Disorders**

Menstruation irregular.

**General Disorders and Administration Site Conditions**

Abscess sterile, impaired healing, oedema peripheral, fatigue, malaise, injection site reaction.

**Investigations**

Intraocular pressure increased, carbohydrate tolerance decreased, blood potassium decreased, urine calcium increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, suppression of reactions to skin tests

a Including masking of infections and latent infections becoming active.
b Peritonitis may be the primary presenting sign or symptom of a gastrointestinal disorder such as perforation, obstruction or pancreatitis (see Section 4.4 Special warnings and precautions for use).
c With or without circulatory collapse, cardiac arrest, bronchospasm, or hypertension.
d Manifestations of latent diabetes mellitus.
e Following a myocardial infarction.
f Hepatitis has been reported with IV administration (see Section 4.4 Special warnings and precautions for use).
g Not a MedDRA preferred term.

**Injury, Poisoning and Procedural Complications**

Spinal compression fracture, tendon rupture.

**Reporting Suspected Adverse Effects**


**4.9 Overdose**

Reports of acute toxicity and metabolic disturbances with glucocorticoids are rare but do occur. There is no clinical syndrome of acute overdosage with SOLU-MEDROL Powder for Injection. Acute overdose may possibly aggravate pre-existing disease states such as ulceration of the gastrointestinal tract, electrolyte disturbances, infections, diabetes and oedema. Repeated high doses of methylprednisolone have caused hepatic necrosis and an increase in amylase.

---

Version: pfpsolv10523

Supersedes: pfpsolv10323

Page 23 of 29
Bradyarrhythmias, ventricular arrhythmias and cardiac arrest have been observed in cases of intravenous administration of high doses of methylprednisolone.

Repeated frequent doses (daily or several times per week) over a protracted period may result in a Cushingoid state. The possibility of adrenal suppression should be guarded against by gradual diminution of dose levels over a period of time.

In the event of an overdose, treatment is symptomatic and supportive, including respiratory and cardiovascular function. In chronic toxicity, fluids and electrolytes should be monitored closely. Serum levels are not clinically useful.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Mechanism of Action
Methylprednisolone is a potent anti-inflammatory steroid. It has a greater anti-inflammatory potency than prednisolone and even less tendency than prednisolone to induce sodium and water retention.

Methylprednisolone sodium succinate has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The relative potency of SOLU-MEDROL Powder for Injection and hydrocortisone sodium succinate, as indicated by depression of eosinophil count, following intravenous administration, is at least four to one. This is in good agreement with the relative oral potency of methylprednisolone and hydrocortisone.

Clinical Trials
No data available.

5.2 Pharmacokinetic properties

Absorption
Peak methylprednisolone plasma levels of approximately 20 µg/mL are reached after IV infusions of 30 mg/kg body weight administered over 20 minutes, or 1 g over 30 to 60 minutes, whilst levels of 42-47 µg/mL are measured after an IV bolus injection of 40 mg. Peak methylprednisolone plasma levels of 34 µg/100 mL are measured after 120 minutes following a 40 mg intramuscular (IM) injection. Lower peak methylprednisolone plasma levels are achieved following IM injection than IV administration. However, the peak plasma value persists for a longer period following IM administration resulting in equivalent quantities of methylprednisolone reaching the plasma independent of the route of administration.

The plasma half-life of methylprednisolone is 2.3 to 4 hours and appears to be independent of the route/pattern of administration. The biological half-life is 12 to 36 hours. The intracellular
activity of glucocorticoids results in the marked variation in the plasma and pharmacological half-lives. Pharmacological activity persists after plasma levels are no longer measurable.

The duration of the anti-inflammatory action of glucocorticoids approximately equals the duration of the hypothalmic-pituitary-adrenal (HPA) axis suppression.

**Metabolism**

*In vivo*, cholinesterases rapidly hydrolyse methylprednisolone sodium succinate to free methylprednisolone. In man, methylprednisolone forms a weak dissociable bond with albumin and transcortin; approximately 40 to 90% of the drug is bound.

Metabolism of methylprednisolone occurs via the hepatic route and is qualitatively similar to metabolism of cortisol. The major metabolites are 20α-hydroxymethylprednisolone and 20-β-hydroxymethylprednisolone.

**Excretion**

The metabolites are mainly excreted in the urine as glucuronides, sulphates and unconjugated compounds. Following intravenous (IV) administration of 

75% of the total radioactivity was recovered in the urine in 96 hours, 9% in faeces after 5 days and 20% in the bile.

**5.3 Preclinical safety data**

**Genotoxicity**

Methylprednisolone sodium succinate has not been formally evaluated for genotoxicity. However, methylprednisolone sulfonate, which is structurally similar to methylprednisolone sodium succinate, was not mutagenic in bacteria (Ames test), or in a mammalian cell gene mutation assay using Chinese hamster ovary cells. Methylprednisolone sulfeptanate did not induce unscheduled DNA synthesis in primary rat hepatocytes. Prednisolone farnesylate, which is also structurally similar to methylprednisolone, was not mutagenic in bacteria but displayed weak clastogenic activity *in vitro* in Chinese hamster lung fibroblasts in the presence of metabolic activation.

**Carcinogenicity**

Methylprednisolone has not been formally evaluated in rodent carcinogenicity studies. Negative results for carcinogenicity have been obtained with various other glucocorticoids, including budesonide, prednisolone and triamcinolone acetonide in mice. However, all three of these compounds were shown to increase the incidence of hepatocellular adenomas and carcinomas after oral administration in a 2-year study in male rats. These tumorigenic effects occurred at doses that are less than the typical clinical doses on a mg/m² basis. Hepatocarcinogenicity is likely to involve an interaction with the glucocorticoid receptor.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

SOLU-MEDROL 40 mg ACT-O-VIAL System

Monobasic sodium phosphate
Dibasic sodium phosphate
Lactose monohydrate
Sodium hydroxide

*Diluent:*
Water for injections

SOLU-MEDROL 125 mg ACT-O-VIAL System

Monobasic sodium phosphate
Dibasic sodium phosphate
Sodium hydroxide

*Diluent:*
Water for injections

SOLU-MEDROL 500 mg, 1 g and 2 g Vials with Diluent

Monobasic sodium phosphate monohydrate
Dibasic sodium phosphate
Sodium hydroxide

*Diluent supplied with Solu-Medrol 500 mg, 1 g and 2 g vials with diluent:*
Benzyl alcohol
Water for injections

SOLU-MEDROL 500 mg and 1 g Plain Vials

Monobasic sodium phosphate
Dibasic sodium phosphate heptahydrate
Sodium hydroxide

6.2 Incompatibilities

To avoid compatibility and stability problems, whenever possible it is recommended that
SOLU-MEDROL (methylprednisolone sodium succinate) be administered separately from
other drugs and as either IV injection, through an IV medication chamber, microburette, or as
an IV “piggy-back” solution. The IV compatibility and stability of methylprednisolone sodium
succinate, either alone in solution or in admixtures with other drugs, is dependent on pH,
concentration, time, temperature, and the ability of methylprednisolone to solubilise itself.

Drugs that are physically incompatible in solution with methylprednisolone sodium succinate
include, but are not limited to: allopurinol sodium, doxapram hydrochloride, tigecycline,
diltiazem hydrochloride, calcium gluconate, vecuronium bromide, rocuronium bromide, cisatracurium besylate, glycopyrrolate, propofol.

6.3 Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special precautions for storage

Store unreconstituted product below 25°C.

When reconstituted using either the diluent provided, or Bacteriostatic Water for Injections with benzyl alcohol, or Sterile Water for Injections, the resulting solution should be used immediately. Discard any unused portion.

6.5 Nature and contents of container

SOLU-MEDROL Powder for Injection is available in the following packages:

1 x 40 mg ACT-O-VIAL and diluent 1 mL in separate chambers.
1 x 125 mg ACT-O-VIAL and diluent 2 mL in separate chambers.
1 x 500 mg Vial and 1 x Diluent 8 mL.
1 x 1 g Vial and 1 x Diluent 15.6 mL.
1 x 2 g Vial and 1 x Diluent 31.2 mL.
1 x 500 mg Plain Vials.
5 x 500 mg Plain Vials.
1 x 1 g Plain Vials.
5 x 1 g Plain Vials.

Not all presentations and pack sizes are marketed.

6.6 Special precautions for disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical properties

Methylprednisolone sodium succinate, USP, occurs as a white, or nearly white, odourless, hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.
Chemical Structure

![Chemical structure diagram]

Molecular formula: $\text{C}_{26}\text{H}_{33}\text{NaO}_8$

Molecular weight: 496.53

CAS Number
2375-03-3

7. MEDICINE SCHEDULE (POISONS STANDARD)

S4 – Prescription Only Medicine

8. SPONSOR

Pfizer Australia Pty Ltd
Level 17, 151 Clarence Street
Sydney NSW 2000
Toll Free Number: 1800 675 229
www.pfizer.com.au

9. DATE OF FIRST APPROVAL

SOLU-MEDROL Vial with Diluent: 2 August 1991
SOLU-MEDROL Plain Vial: 22 November 1994
SOLU-MEDROL ACT-O-VIAL: 23 September 2010

10. DATE OF REVISION

4 May 2023

© Registered trademark
## Summary Table of Changes

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>• Addition of a warning statement regarding Tumour Lysis Syndrome (TLS).</td>
</tr>
<tr>
<td>4.8</td>
<td>• Replacement of MedDRA PT “Hypopituitarism” with PT “Hypothalamic-pituitary-adrenal axis suppression” for the ADR “pituitary-adrenal axis suppression”</td>
</tr>
</tbody>
</table>